The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Share News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: -0.25 (-3.28%)
Spread: 0.25 (3.448%)
Open: 7.625
High: 7.625
Low: 7.375
Prev. Close: 7.625
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Ixico revenue falls, Solid State boosts profit

Tue, 05th Dec 2023 14:31

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Ixico PLC - London-based precision analytics company working to advance investigational therapies for neurological diseases - Revenue for the year that ended on September 30 falls 23% to GBP6.7 million from GBP8.6 million the year before. Company swings to GBP1.4 million pretax loss following a GBP885,000 profit. Total operating expenses increase to GBP5.1 million from GBP5.0 million. Ixico says revenue drop was expected and caused by the now-realised impact of clients ceasing multiple large "failed" trials across 2021 and early 2022. Expects to deliver roughly flat revenue in the current financial year before returning to growth in 2025.

----------

Supply@Me Capital PLC - London-based fintech platform provider - Says it has so far received GBP1.4 million from The AvantGarde Group SpA as a result of contractual payments. An additional GBP1.5 million remains outstanding. Also says it has made significant progress in the formalisation of its first White-Label IM agreement with an Italian banking group with a transaction valued at up to EUR10 million. Company is also working to finalise a framework to issue security tokens up to USD100 million to be subscribed in tranches.

----------

Lindsell Train Investment Trust PLC - London-based, rail-focused investment trust - Net asset value at September 30 is GBP968.75 per share, down from GBP1,056.95 at March 31. NAV total return for the six months to September 30 is negative 3.6%, underperforming the MSCI World Index with positive 4.5%. Says performance was impacted by high interest rates and inflation, and believes it may have to reduce its dividend. Notes reduced investor risk appetites and increased market volatility.

----------

Marechale Capital PLC - London-based corporate finance adviser - Revenue for the half year that ended on October 31 increased 91% to GBP320,603 from GBP168,001. Cost of sales more than doubles to GBP226,790 from GBP95,981. Pretax loss narrows to GBP155,803 from GBP179,502. Marechale says market is still challenging, especially in the hospitality sector, but that it remains positive about the outlook for its investments.

----------

Anglesey Mining PLC - Base metals miner with operations in North Wales, Sweden and Canada - Says drilling of the NCZ001 hole in the Northern Copper Zone at its Parys Mountain project on the Isle of Anglesey commenced on October 27, and is expected to complete over the next week. Expects results in the first quarter of 2024. Says initial logging suggests sulphide mineralisation commencing at around 350 metres deep. Chief Executive Jo Battershill says initial core is "very encouraging" as "we are seeing a significant amount of quartz veins within the system..[which] contain encouraging amounts of chalcopyrite, sphalerite, and galena – the key minerals that host copper, zinc and lead."

----------

Psych Capital PLC - London-based psychedelic medicines media firm and investor - Oscillate PLC continues to own 46.0 million shares in Psych, representing 12.75% of its issued share capital, following Psych's acquisition of Short Wave Pharma Inc which completed in November. Oscillate says it will continue to assess the investment to ascertain an exit opportunity. Says it meanwhile remains "optimistic at the advances that the Short Wave acquisition represents in the innovative psychedelics space." Oscillate also says that trials are due to start in the first quarter of 2024.

----------

Solid State PLC - Redditch, England-based supplier & design-in manufacturer of computing, power, and communications products - Pretax profit for the six months to September 30 is GBP6.1 million, up 45% from GBP4.2 million the prior year. Revenue increases 48% to GBP88.1 million from GBP59.4 million. Company declares 7.0 pence per share interim dividend, up 8% from 6.5p the year before. Says it is confident in meeting expectations for full-year results thanks to "record billings" and a "stable six-month order book". Open order book at October 31 stood at GBP108.6 million, slightly down from GBP112.5 million at September 30, 2022.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Oct 2021 09:33

Ixico FY revenues projected to beat expectations

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were projected to have beat expectations despite falling shy of prior year comparatives.

Read more
22 Sep 2021 11:19

Ixico secures new contract valued at more than $750,000

(Sharecast News) - AI data analytics firm Ixico has secured a new contract valued at more than $750,000 over two years for advanced neuroimaging solutions.

Read more
8 Sep 2021 12:47

Ixico awarded phase 1 clinical trial contract

(Sharecast News) - Neuroscience artificial intelligence (AI) company Ixico has been awarded a contract by a new biopharmaceutical client to support its phase 1 multiple system atrophy clinical trial, it announced on Wednesday.

Read more
6 Aug 2021 14:53

Ixico confident as full-year revenue, earnings decline

(Sharecast News) - Data analytics company Ixico updated the market on its trading on Friday, confirming that despite a "challenging" business environment, it expected to deliver £8.7m in revenues for the 2021 financial year.

Read more
26 Apr 2021 09:06

Ixico H1 revenues grow despite Covid-19 impacts on clinical development sector

(Sharecast News) - Clinical research firm Ixico said on Monday that revenues were expected to have improved in the six months ended 31 March, despite the impacts of the Covid-19 pandemic on the clinical development sector.

Read more
15 Mar 2021 10:13

Ixico strikes collaboration deal with Microsoft

(Sharecast News) - Data analytics company Ixico said on Monday that it had struck a collaboration agreement with tech giant Microsoft to develop its artificial intelligence analytics platform for the global pharmaceutical industry.

Read more
10 Mar 2021 14:30

Ixico selected for Alzheimer's clinical trial

(Sharecast News) - Neuroscience artificial intelligence (AI) analytics company Ixico has been selected by a current mid-sized biopharmaceutical client to support a phase 2 Alzheimer's disease clinical trial, it announced on Wednesday.

Read more
24 Dec 2020 12:20

Ixico awarded ?3.4m contract by existing client

(Sharecast News) - Artificial intelligence (AI) data analytics company Ixico has been awarded a £3.4m contract to run over 4.5 years by an existing client, it announced on Thursday, for a spinocerebellar ataxia type-3 (SCA3) trial.

Read more
8 Dec 2020 09:26

Ixico to provide neuroimaging solutions to unnamed global pharmaceutical group

(Sharecast News) - Data analytics firm Ixico has secured a contract for neuroimaging solutions with a "large global pharmaceutical company".

Read more
27 Nov 2020 12:09

Ixico executes contract for Huntington's disease clinical trial

(Sharecast News) - Neuroscience data analytics company Ixico has executed a contract to provide neuroimaging services that would support a phase 1b and 2 clinical trial for Huntington's disease, it announced on Friday.

Read more
3 Nov 2020 10:43

Ixico wins new contracts in Alzheimer's clinical trials

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.

Read more
22 Oct 2020 15:00

Ixico secures two Huntington's disease clinical trial contracts

(Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Huntington's disease clinical trials.

Read more
19 Oct 2020 09:38

Ixico FY revenues grow by more than a quarter

(Sharecast News) - AI data analytics company Ixico said on Monday that full-year revenues were up year-on-year as its data analytics service strategy continued to drive growth.

Read more
16 Oct 2020 16:23

Ixico enters deal with NUY Langone Health for drug trial

(Sharecast News) - Data analytics company Ixico has entered into an agreement with NYU Langone Health to support a trial to determine if the immunosuppressant drug Sirolimus, approved by the FDA to prevent organ transplant rejection and for the treatment of a rare and progressive lung disease called lymphangioleiomyomatosis, is also able to slow the progression of disease in people with multiple system atrophy (MSA).

Read more
24 Sep 2020 16:30

Ixico joins Friedreich's Ataxia research consortium

(Sharecast News) - Data analytics company Ixico has entered into a five-year collaboration with the Friedreich's Ataxia Research Alliance (FARA), it announced on Thursday, which it described as a non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreich's Ataxia (FA).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.